Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OrganoORGJF 94 Equity-to-Asset is 0.64 as of Mar. 2026, which is 12% above its 10-year median of 0.57. GuruFocus rates ORGJF with a GF Score™ of 94/100 and a GF Value™ of $78.54 (Modestly Overvalued). Among 3,086 Industrial Products companies, Organo ranks better than 64% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Organo's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $901 Mil. Organo's Total Assets for the quarter that ended in Mar. 2026 was $1,417 Mil.
Therefore, Organo's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.64.
The historical rank and industry rank for Organo's Equity-to-Asset or its related term are showing as below:
ORGJF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51 Med: 0.57 Max: 0.64
Current: 0.64
During the past 13 years, the highest Equity to Asset Ratio of Organo was 0.64. The lowest was 0.51. And the median was 0.57.
ORGJF's Equity-to-Asset is ranked better than 64% of 3086
companies
in the Industrial Products industry
Industry Median: 0.56
vs ORGJF: 0.64
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Organo Equity-to-Asset Related Terms
Organo Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Organo's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORGJF vs VLTO, ZWS, CECO: Equity-to-Asset Comparison
For the Pollution & Treatment Controls subindustry, Organo's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organo Equity-to-Asset vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Organo's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Organo's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Organo's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organo (ORGJF) has a Equity-to-Asset of 0.64 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Organo and its competitors. This is 12% above median its historical median of 0.57. Over the past decade, Organo's Equity-to-Asset has ranged from 0.51 to 0.64. According to the industry distribution chart, Organo ranks #1111 out of 3086 companies in the Industrial Products industry, placing it in the top 36%.
Is Organo's Equity-to-Asset too high?
Organo's current Equity-to-Asset of 0.64 is 12% above median its 10-year median of 0.57. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 0.64. The Industrial Products industry median Equity-to-Asset is 0.56. Organo's value of 0.64 is 14.3% above this industry median. Based on the distribution chart, Organo ranks #1111 out of 3086 companies in the Industrial Products industry, which is above the industry midpoint. Overall, Organo has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Organo's Equity-to-Asset compare to VLTO and ZWS?
According to the Industrial Products industry distribution chart, Organo ranks #1111 out of 3086 companies for Equity-to-Asset. This puts Organo in the upper half of its industry. The industry median Equity-to-Asset is 0.56. Organo's value of 0.64 is 14.3% above this benchmark. Historically, Organo's own Equity-to-Asset has ranged from 0.51 to 0.64 over the past decade. While the company's 10-year median is 0.57 vs. the industry median of 0.56, Organo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for an Industrial Products company?
The median Equity-to-Asset among Industrial Products companies is 0.56, based on 3,086 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organo's current Equity-to-Asset of 0.64 is 14.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Organo and its competitors. For the Industrial Products industry, the median Equity-to-Asset is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organo's current Equity-to-Asset is 0.64, which is 12% above median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organo stock overvalued right now?
Based on GuruFocus' analysis, Organo (ORGJF) is currently considered Modestly Overvalued. The stock's GF Value™ is $78.54, compared to a current price of $93.00 — trading 18.4% above its estimated fair value. The current Equity-to-Asset is 0.64, which is 12% above median its 10-year median of 0.57 and 14.3% above the Industrial Products industry median of 0.56. Organo's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Organo (ORGJF), the current Equity-to-Asset is 0.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organo (ORGJF) Overvalued in 2026?
Based on GuruFocus' analysis, Organo stock appears to be overvalued.
The current stock price of $93.00 is trading 18.4% above its estimated GF Value™ of $78.54.
GuruFocus considers Organo to be Modestly Overvalued.
Key valuation signals for ORGJF:
Equity-to-Asset: 0.64 (12% above median its 10-year median of 0.57)
GF Value™: $78.54 vs. price of $93.00 (18.4% above fair value)
Industry Position: 14.3% above the Industrial Products median (#1111 of 3086)
No single metric tells the full story. See the ORGJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organo Corp is a Japan-based company mainly engaged in the water treatment engineering business. The company operates in two business divisions namely water treatment engineering and functional product. Its water treatment engineering business includes manufacturing, delivery and maintenance of pure water systems, ultra-pure water systems and wastewater treatment systems for industries, condensate de mineralizers for power stations, waterworks and sewage treatment systems for the public sector. The functional product business encompasses the sale of standardized water treatment equipment, water treatment chemicals, and food processing materials.
94GF Score
Get the complete analysis for ORGJF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORGJF has been successfully added to your 
